Business news, market intelligence, and global industry analysis.
The Latest

Dr. Reddy’s Laboratories launches antimuscarinic drug Toviaz generic in US

bySrinath
July 10, 2022
Total
0
Shares
0
0
0

Dr. Reddy’s Laboratories has launched Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets in the US market following the approval of the US Food and Drug Administration (FDA).

The product is generic of Toviaz (fesoterodine fumarate) Extended-Release Tablets of Pfizer, an antimuscarinic drug used for the treatment of certain bladder problems.

Dr. Reddy’s Laboratories launches antimuscarinic drug Toviaz generic in US
Dr. Reddy’s Laboratories launches antimuscarinic drug Toviaz generic in US. Photo courtesy of Karthikndr/Wikimedia Commons.

According to IQVIA, the Toviaz brand had sales of nearly $211 million MAT in the US for the most recent 12 months ending in May 2022.

Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets come in 4mg and 8mg tablets, each in bottle count sizes of 30.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Sanofi advances flu vaccine production with FDA-approved strains for 2025-26 season
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Themis Bioscience rakes in €40m to advance MV-CHIK Chikungunya vaccine

Themis Bioscience, an Austrian biopharma company, has raised €40 million in a Series D financing round backed by a US/EU Consortium to advance its MV-CHIK Chikungunya vaccine into a phase 3 clinical trial program. The funding round of the Austrian pharma company was co-led by new investors – Farallon Capital and Hadean Ventures. Pharma giant MSD […]

The post Themis Bioscience rakes in €40m to advance MV-CHIK Chikungunya vaccine appeared first on PharmaNewsDaily.com.

bypharmanewsdaily